Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2002
|
| gptkbp:ATCCode |
B01AC21
|
| gptkbp:CASNumber |
81846-19-7
|
| gptkbp:chemicalFormula |
C23H34O5
|
| gptkbp:eliminationHalfLife |
4 hours
|
| gptkbp:genericName |
gptkb:treprostinil
|
| https://www.w3.org/2000/01/rdf-schema#label |
Remodulin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:United_Therapeutics
|
| gptkbp:mechanismOfAction |
prostacyclin analogue
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinBinding |
91%
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
nausea
diarrhea headache jaw pain infusion site pain |
| gptkbp:usedFor |
pulmonary arterial hypertension
|
| gptkbp:bfsParent |
gptkb:United_Therapeutics
|
| gptkbp:bfsLayer |
7
|